$SPRY

ARS Pharmaceuticals (SPRY) faces a securities class action lawsuit alleging it failed to disclose risks of delayed CVS Caremark formulary coverage for its allergy treatment, neffy. The stock fell 23.9% on June 24, 2026, after the company announced a delay in coverage until January 2027. The lawsuit claims this delay was a material risk not properly disclosed to investors, affecting the summer and back-to-school allergy seasons. The deadline to apply for lead plaintiff is October 5, 2026.

ARS Pharmaceuticals (SPRY) director Richard Lowenthal plans to sell 840 shares under Rule 144, following recent sales of 125,000 shares in August 2026 totaling $786,390. The sale is related to a stock option exercise dated September 2, 2026, and will be facilitated by Morgan Stanley.

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ:SPRY) and certain officers, alleging securities law violations. The lawsuit covers investors who acquired ARS securities between March 9, 2026, and June 24, 2026, claiming misleading statements about insurance coverage for neffy. Investors have until October 5, 2026, to request lead plaintiff status.

ARS Pharma (SPRY) reported Q2 2026 U.S. net product revenue of $26.2M, with total market share reaching 5%, up from 2.5% YoY. Neffy's market share in targeted areas hit 8%, driven by 16,000+ unique prescribers. The company aims to expand into the CSU market and expects cash flow breakeven by late 2027. Total revenue was $33.7M, with operating expenses at $95.1M. ARS plans to reduce SG&A and R&D expenses by over 40% in the second half of 2026.

ARS Pharmaceuticals (SPRY) reported Q2 2026 earnings, with Neffy's US market share doubling to 5% YoY. CEO Donn Casale outlined priorities including targeted commercial efforts and cost cuts. Revenue was $33.7M, with operating expenses at $95.1M. The company plans to reduce spending by over 40% in H2 2026 and aims for cash flow breakeven by late 2027. Short interest is high at 31.17% of the float.

A securities class action lawsuit has been filed against ARS Pharmaceuticals (NASDAQ: SPRY), alleging the company failed to disclose risks related to a delayed CVS Caremark formulary decision. The stock fell 23.9% on June 25, 2026, after the company announced no coverage decision for neffy in the July 1, 2026 cycle. The complaint claims investors lost $2.52 per share, with the lead plaintiff deadline set for October 5, 2026.

ARS Pharmaceuticals (SPRY) shares fell 23% after-hours as it reported no new major commercial insurance coverage for Neffy effective July 1. The company is in negotiations with payers and secured additional Medicaid coverage. ARS lowered 2026 operating expense guidance to $248M and reaffirmed cash flow break-even target for 2027. Neffy had 120,000 U.S. patients in Q1 and $72.2M in 2025 net sales, 86% of total revenue.

ARS Pharmaceuticals (SPRY) reported Q2 2026 revenue of $33.7M, up from $15.7M a year earlier, driven by $26.2M U.S. net product revenue from neffy. Net loss widened to $62.3M ($0.63/share). The company cut broad consumer ads, targeted high-volume prescribers, appointed Meg Smith CCO, and expects H2 2026 SG&A and R&D of $114M-$126M.

ARS Pharmaceuticals (NASDAQ: SPRY) shares fell about 7% after an FDA-related setback and a CVS Caremark coverage delay that pushed broader coverage to at least January 2027, according to the article. It also cites a securities class action alleging misstatements tied to the timing. The piece notes LTM revenue near $84M, cash about $144M, and quarterly operating cash burn around $61M.

US stock index futures edged higher after the S&P 500 and Nasdaq 100 hit record levels. Tech and AI-related shares led, with Sandisk up in premarket after JPMorgan’s overweight rating. Reuters said the BOJ is considering a September rate hike. Several single-stock moves followed earnings, guidance, tariffs, and analyst actions, including AVAV, AEHR, SPRY, CAPR, NU, RDDT, and GLOB.